THE FRENCH NATIONAL NAFLD COHORT (FRench pAtients With MEtabolic Steatosis)
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorAssistance Publique - Hôpitaux de Paris
About this trial
The main objective of this cohort study is to determine genetic, clinical biologic and metabolic factors associated with patient heterogeneity in regards to severity of NAFLD at diagnosis as well as during the clinical course.
* at diagnosis, with the aim to better characterize patients of different severity and improve our understanding of clinical and histological heterogeneity at diagnosis * during the clinical course to better understand and predict disease progression in terms notably of fibrosis progression and progression to cirrhosis
Eligibility criteria
Qualifiers
Age ≥18 years
Patients with a confirmed diagnosis of NAFLD
Patients affiliated to French social security
Written informed consent signed by the patient
Disqualifiers
Refusal or inability (lack of capacity) to give informed consent.
Average alcohol ingestion greater than 21/14 units/week (males/females) in the preceding 6 months or history of sustained excessive consumption of alcohol in past 5 years.
History or presence of Type 1 diabetes mellitus.
Presence of any other form of chronic liver disease except NAFLD
Trial design
Treatments tested in this trial
- Biological specimens
- Additional visit
Treatment groups
900 Participants
are divided into 1 treatment groupLocations
Sponsors and collaborators
Source ClinicalTrials.gov